Keep in mind that those results were with a safety dose of a weaker version of the neutrophils they're currently using. Their mouse studies with stronger neutrophils and higher dosing resulted in 100% survival rates and tumor elimination. What the safety study does prove is that the mechanism of action works the same way in humans as in mice. It also proves safety. That's why I think they have a pretty good chance of succeeding. Of course, biotech is a field riddled with failure, so I may very well be wrong, but I'm optimistic. Luckily, we'll only have to wait a couple of years before we know if it works.

perhaps a recurring issue on the seriousness level of recurring eczema. something that keeps popping up, but easily cleared up.